La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Nevro Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Nevro ha un patrimonio netto totale di $274.3M e un debito totale di $218.4M, che porta il suo rapporto debito/patrimonio netto a 79.6%. Le sue attività totali e le sue passività totali sono rispettivamente $603.3M e $329.1M.

Informazioni chiave

79.6%

Rapporto debito/patrimonio netto

US$218.40m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$273.69m
Patrimonio netto	US$274.25m
Totale passività	US$329.08m
Totale attività	US$603.34m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Aug 11

Nevro: Not Having My Back

Aug 09

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Jul 16

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

May 01

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Feb 25

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Jan 08

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nov 16

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Sep 01

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Jul 10

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Feb 28

Nevro falls to 52-week low; down ~49% over last year

Feb 22

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Feb 14

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Jan 13

Nevro: Opportunity Overshadowed By Weaknesses

Dec 07

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Oct 26

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Oct 13

Nevro gets FDA approval for Costa Rica manufacturing operations

Oct 04

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Oct 02

Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation

Sep 07

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Jun 17

Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery

Jun 10

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $486.2M ) di NVRO superano le sue passività a breve termine ( $101.9M ).

Passività a lungo termine: Le attività a breve termine di NVRO ( $486.2M ) superano le sue passività a lungo termine ( $227.1M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: NVRO ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di NVRO è aumentato da 77.5% a 79.6% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: NVRO ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: NVRO ha una liquidità sufficiente per più di 3 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 9.5 % ogni anno

Nevro Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Recent updates

Consensus EPS estimates fall by 21%

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Nevro: Not Having My Back

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 25% to US$11.07

Nevro Revises Earnings Guidance for the Full Year 2024

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Nevro Corp. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$2.31 loss

Price target decreased by 12% to US$16.63

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Price target decreased by 9.5% to US$19.40

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Full year 2023 earnings: EPS exceeds analyst expectations

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$26.37

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Consensus EPS estimates fall by 16%

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Price target decreased by 23% to US$28.80

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Price target decreased by 8.5% to US$37.57

Independent Director recently bought US$172k worth of stock

Price target decreased by 8.5% to US$38.43

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Nevro falls to 52-week low; down ~49% over last year

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Consensus forecasts updated

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Nevro: Opportunity Overshadowed By Weaknesses

Price target decreased to US$47.73

Consensus forecasts updated

Price target decreased to US$50.36

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Price target decreased to US$53.91

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro gets FDA approval for Costa Rica manufacturing operations

Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro Corp. Announces Executive Changes

Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation

Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy

Consensus forecasts updated